<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">BMC Endocr Disord</journal-id><journal-id journal-id-type="iso-abbrev">BMC Endocr Disord</journal-id><journal-title-group><journal-title>BMC Endocrine Disorders</journal-title></journal-title-group><issn pub-type="epub">1472-6823</issn><publisher><publisher-name>BioMed Central</publisher-name><publisher-loc>London</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">25990414</article-id><article-id pub-id-type="pmc">4443632</article-id><article-id pub-id-type="publisher-id">12</article-id><article-id pub-id-type="doi">10.1186/s12902-015-0012-7</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title>Low-dose combined oral contraceptive use is associated with lower bone mineral content variation in adolescents over a 1-year period</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Biason</surname><given-names>Talita Poli</given-names></name><address><email>talitapoli@uol.com.br</email></address><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Goldberg</surname><given-names>Tamara Beres Lederer</given-names></name><address><email>tamara@fmb.unesp.br</email></address><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author"><name><surname>Kurokawa</surname><given-names>Cilmery Suemi</given-names></name><address><email>kurokawa@fmb.unesp.br</email></address><xref ref-type="aff" rid="Aff2"/></contrib><contrib contrib-type="author"><name><surname>Moretto</surname><given-names>Maria Regina</given-names></name><address><email>rmoretto@fmb.unesp.br</email></address><xref ref-type="aff" rid="Aff2"/></contrib><contrib contrib-type="author"><name><surname>Teixeira</surname><given-names>Altamir Santos</given-names></name><address><email>altamirsteixeira@gmail.com</email></address><xref ref-type="aff" rid="Aff3"/></contrib><contrib contrib-type="author"><name><surname>Nunes</surname><given-names>H&#x000e9;lio Rubens de Carvalho</given-names></name><address><email>helio@conspart.com.br</email></address><xref ref-type="aff" rid="Aff4"/></contrib><aff id="Aff1"><label/>Department of Pediatrics, Adolescent Medicine Discipline, Graduate Program in Gynecology, Obstetrics, and Mastology, Botucatu School of Medicine, S&#x000e3;o Paulo State University (UNESP), S&#x000e3;o Paulo, Brazil </aff><aff id="Aff2"><label/>Clinical and Experimental Pediatrics Research Center, Department of Pediatrics, Botucatu Medical School, S&#x000e3;o Paulo State University (UNESP), S&#x000e3;o Paulo, Brazil </aff><aff id="Aff3"><label/>Department of Tropical Diseases and Diagnostic Imaging, Botucatu School of Medicine, S&#x000e3;o Paulo State University (UNESP), S&#x000e3;o Paulo, Brazil </aff><aff id="Aff4"><label/>Statistical Consultant, Botucatu School of Medicine, S&#x000e3;o Paulo State University (UNESP), S&#x000e3;o Paulo, Brazil </aff></contrib-group><pub-date pub-type="epub"><day>3</day><month>4</month><year>2015</year></pub-date><pub-date pub-type="pmc-release"><day>3</day><month>4</month><year>2015</year></pub-date><pub-date pub-type="collection"><year>2015</year></pub-date><volume>15</volume><elocation-id>15</elocation-id><history><date date-type="received"><day>3</day><month>4</month><year>2014</year></date><date date-type="accepted"><day>26</day><month>3</month><year>2015</year></date></history><permissions><copyright-statement>&#x000a9; Biason et al.; licensee BioMed Central. 2015</copyright-statement><license license-type="open-access"><license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0">http://creativecommons.org/licenses/by/4.0</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/publicdomain/zero/1.0/">http://creativecommons.org/publicdomain/zero/1.0/</ext-link>) applies to the data made available in this article, unless otherwise stated.</license-p></license></permissions><abstract id="Abs1"><sec><title>Background</title><p>Low-dose combined oral contraceptives (COCs) can interfere with bone mass acquisition during adolescence. This study aimed to evaluate bone mineral density (BMD) and bone mineral content (BMC) in female adolescents taking a standard low-dose COC (ethinylestradiol 20&#x000a0;&#x003bc;g/desogestrel 150&#x000a0;&#x003bc;g) over a 1-year period and to compare their data with those of healthy adolescents from the same age group not taking COCs.</p></sec><sec><title>Methods</title><p>This was a non-randomized parallel-control study with a 1-year follow-up. Sixty-seven adolescents aged from 12 to 19&#x000a0;years, divided into COC users (n&#x02009;=&#x02009;41) taking 20&#x000a0;&#x003bc;g ethinylestradiol/150&#x000a0;&#x003bc;g desogestrel and COC non-user controls (n&#x02009;=&#x02009;26), were evaluated by bone densitometry examinations at baseline and after 12&#x000a0;months. Comparisons between the groups at the study onset were performed using the Mann&#x02013;Whitney test with the significance level fixed at 5% or p&#x02009;&#x0003c;&#x02009;0.05. Comparisons between the groups at the study onset and after 12&#x000a0;months were based on variations in the median percentages for bone mass variables.</p></sec><sec><title>Results</title><p>The COC users presented with low bone mass acquisition in the lumbar spine, and had BMD and BMC median variations of 2.07% and +1.57%, respectively, between the measurements at baseline and 12&#x000a0;months. The control group had median variations of +12.16% and +16.84% for BMD and BMC, respectively, over the same period. The total body BMD and BMC showed similar evolutions during the study in both groups. Statistical significance (p&#x02009;&#x0003c;&#x02009;0.05) was seen for the BMC percentage variation between COC users and non-users.</p></sec><sec><title>Conclusions</title><p>Use of a low-dose COC (ethinylestradiol 20&#x000a0;&#x003bc;g/desogestrel 150&#x000a0;&#x003bc;g) was associated with lower bone mass acquisition in adolescents during the study period.</p></sec><sec><title>Trial registration</title><p>Registry Number, <ext-link ext-link-type="uri" xlink:href="http://www.ensaiosclinicos.gov.br/rg/RBR-5h9b3c/">RBR-5h9b3c</ext-link>.</p></sec></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Adolescent</kwd><kwd>Bone density</kwd><kwd>Bone mineral content</kwd><kwd>Contraceptives</kwd><kwd>Osteoporosis</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; The Author(s) 2015</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1" sec-type="introduction"><title>Background</title><p>Osteoporosis is a major public health issue that results in severe consequences for patients and great expense for public health systems through costly efforts to prevent or treat this disease. Although the disease manifests later in life, measures aimed at its prevention must be adopted during infancy and adolescence, because around 90% of the total bone mass is acquired during that time [<xref ref-type="bibr" rid="CR1">1</xref>-<xref ref-type="bibr" rid="CR4">4</xref>]. Inadequate bone mass acquisition during infancy and adolescence is one of the main determinants in the occurrence of osteopenia and osteoporosis later in life [<xref ref-type="bibr" rid="CR1">1</xref>,<xref ref-type="bibr" rid="CR4">4</xref>,<xref ref-type="bibr" rid="CR5">5</xref>]. Genetic factors are responsible for 60&#x02013;80% of the bone mass increment [<xref ref-type="bibr" rid="CR6">6</xref>,<xref ref-type="bibr" rid="CR7">7</xref>], while the remaining bone mass is achieved through other factors such as adequate calcium intake, sun exposure, adequate dietary and supplemental vitamin D intake, and regular physical activity [<xref ref-type="bibr" rid="CR8">8</xref>].</p><p>Additional factors such as gonadal hormones, particularly estrogen, play crucial roles in bone mass acquisition during adolescence. Experimental studies have shown that estrogen reduces osteoclast formation (osteoclastogenesis) and activity, thereby decreasing bone reabsorption, mainly through increased apoptosis. Furthermore, estrogen positively affects the formation, differentiation, proliferation, and activity of osteoblasts, which stimulate bone formation [<xref ref-type="bibr" rid="CR9">9</xref>-<xref ref-type="bibr" rid="CR11">11</xref>]. A more specific activity of 17&#x003b2;-estradiol was detected in cell culture, as it negatively modulated osteoclasts, either indirectly by suppressing osteoblastic production of various proresorptive paracrine factors such as interleukin-1&#x003b2;, interleukin-6, and tumor necrosis factor-&#x003b1;, or directly through an estrogen receptor (ER)-mediated mechanism on target cells [<xref ref-type="bibr" rid="CR12">12</xref>,<xref ref-type="bibr" rid="CR13">13</xref>]. In addition to the indicated mechanisms, estradiol increased the production of osteoprotegerin by osteoblasts through activation of the estrogen receptor ER&#x003b1;. The cytokine osteoprotegerin is considered to be a potent inhibitor of bone resorption [<xref ref-type="bibr" rid="CR13">13</xref>].</p><p>Therefore, the use of combined oral contraceptives (COCs), which alter the physiology of the hypothalamic&#x02013;pituitary&#x02013;gonadal axis, and consequently estrogen levels, may interfere with adolescent bone mass acquisition. Because COCs are the most common contraceptive method used by adolescents and young adults in the United States [<xref ref-type="bibr" rid="CR14">14</xref>], studies have investigated the consequences of COC use on bone mineral density (BMD) in users at these ages [<xref ref-type="bibr" rid="CR15">15</xref>,<xref ref-type="bibr" rid="CR16">16</xref>]. However, some of these studies produced results that have remained controversial.</p><p>Gai et al. [<xref ref-type="bibr" rid="CR15">15</xref>] followed 450 adolescents aged between 16 and 18&#x000a0;years who were taking COCs with 35 or 30&#x000a0;&#x003bc;g ethinylestradiol (EE), and observed no significant differences in BMD between users and non-users after 2&#x000a0;years of observation. Pikkarainen et al. [<xref ref-type="bibr" rid="CR16">16</xref>] analyzed the effects of COCs containing 20&#x02013;35&#x000a0;&#x003bc;g EE on bone mass in adolescents aged between 12 and 19&#x000a0;years, and found a smaller increase in bone mineral content (BMC) in users taking COC for over 2&#x000a0;years. However, neither of these studies evaluated the effects on the bone mass in these young people when the COC was no longer taken. Furthermore, specific formulations designed for this age group aim to minimize the risks of thromboembolism and other adverse effects associated with COC use. Nevertheless, the available data on the impact of COC use during adolescence are fairly inconclusive, and therefore new studies on subjects within delimited age groups using the same COC formulations are relevant [<xref ref-type="bibr" rid="CR17">17</xref>].</p><p>This study aimed to evaluate BMC and BMD in adolescents using COCs containing 20&#x000a0;&#x003bc;g EE and 150&#x000a0;&#x003bc;g desogestrel and to compare their data with those from adolescents not using these contraceptives.</p></sec><sec id="Sec2" sec-type="methods"><title>Methods</title><p>This was a non-randomized parallel-control study. The participants were followed up for 12&#x000a0;months and data were collected between 2010 and 2012. We recruited 67 healthy female volunteers aged between 12 and 19&#x000a0;years, who attended the Adolescent Medicine Outpatient Clinic of Botucatu University Hospital, S&#x000e3;o Paulo State University (UNESP), S&#x000e3;o Paulo, Brazil. The volunteers were post-menarche, had regular menstrual cycles, and had no oligomenorrhea/amenorrhea conditions. None of the participants had previously used hormonal contraceptives, and none of them were pregnant before or at the time of the study. All participants were non-smokers and non-drinkers, and did not participate in sporting activities besides the 2-hour physical activity performed once a week during school hours. Of the participants, 41 were medically advised to start using the COC containing 20&#x000a0;&#x003bc;g EE and 150&#x000a0;&#x003bc;g desogestrel when they were enrolled in the study, and thus constituted the test group (avoidance of unintended pregnancy). The control group consisted of 26 adolescents not using any type of hormonal COCs.</p><p>Height and body mass index (BMI) were between the 5th and 95th percentiles for their age group, according to the Centers for Disease Control and Prevention criteria [<xref ref-type="bibr" rid="CR18">18</xref>]. The health-related exclusion criteria adopted for the study were: history of prematurity or low birth weight; prolonged steroid treatment or use of calcium or iron supplements 12&#x000a0;months prior to the study; diabetes mellitus; acute or chronic malnutrition; congenital or acquired bone diseases; gastrointestinal malabsorption; history of nephropathy with or without chronic renal insufficiency; endocrinopathies; early or late puberty; chronic drug consumption; cystic fibrosis; and celiac disease. Other exclusion criteria included use of medications known to negatively affect bone metabolism such as anticonvulsants and antacids with aluminum, solely vegetarian or high-fiber-containing diet, and daily consumption of more than 300&#x000a0;mg of caffeine or more than 500&#x000a0;mL of cola-based soft drinks.</p><p>Blood samples were taken from the COC users at 6&#x000a0;months after entering the study for measurement of estradiol levels by chemiluminescent microparticle immunoassay using an ARCHITECT&#x000ae; Estradiol Kit (Abbott Laboratories, Abbott Park, IL) to indirectly determine the effects of EE use. The percent recovery of estradiol in the presence of ethynylestradiol (interferent content) with this method was reported to be 88.6%.</p><p>This study was approved by the Research Ethics Committee of the Botucatu School of Medicine, S&#x000e3;o Paulo, Brazil. All subjects and their families gave written informed consent for participation in the study.</p><p>The COC users underwent anthropometric measurements and evaluation of their nutritional and bone mass at baseline and after 12&#x000a0;months to measure the variables to be examined. The control COC non-users were evaluated for the same variables as the COC users at baseline and after 12&#x000a0;months. Appointments were scheduled for each group every 3&#x000a0;months or according to each patient&#x02019;s needs. Dietary assessment was performed once at baseline through a 3-day food record to verify calcium intake and factors that could interfere with its bioavailability. The participants were weighed using a Filizola electronic scale with 0.1-kg accuracy and measured for height with a wooden height gauge with 0.1-cm accuracy, and underwent a physical examination to detect any potential alterations. A pubertal stage evaluation was performed according to Tanner by two professionals highly experienced in this function [<xref ref-type="bibr" rid="CR19">19</xref>].</p><p>Anamnesis was performed during all visits, so that any problems or inadequacies with the medication use could be recorded. To evaluate skeletal maturation, bone age (BA) was obtained by the Greulich&#x02013;Pyle method [<xref ref-type="bibr" rid="CR20">20</xref>]. Bone mass was evaluated by bone densitometry via dual-energy X-ray absorptiometry (DXA) using a Hologic QDR 4500 Discovery A apparatus (Hologic Inc., Bedford, MA). The bone mass evaluation was adjusted using pediatric software; BMC values were expressed in grams and BMD values were expressed in grams per square centimeter. The areas analyzed by DXA were the lumbar spine region, the whole body, and the whole body without the cephalic region as per the International Society for Clinical Densitometry recommendations, which indicate that these regions have the best accuracy for the infancy and adolescence age ranges [<xref ref-type="bibr" rid="CR21">21</xref>]. The DXA instrument was calibrated by daily scanning of a hydroxyapatite spine phantom. Machine drift was not observed during the study. The coefficient of variation was estimated from repeated measurements (twice) obtained from 30 patients representative of the clinic&#x02019;s patient population for all regions mentioned (lumbar spine and total body) after each patient had been repositioned before scanning. With the results in hand, CVs of 0.6% and 1.3% were obtained for the lumbar spine and for the whole body, respectively. All evaluations were made by the same blinded, experienced technician, who also performed the densitometry examinations.</p><sec id="Sec3"><title>Statistical analysis</title><p>We considered the same standard deviation of 2 for both groups, with type I and type II errors equal to 0.05 and 0.20, respectively, and determined that a sample of 12 adolescents per group would be able to detect variation differences higher than 2.29% between the groups.</p><p>Age, weight, height, BMI, and BA presented asymmetric distributions. The Mann&#x02013;Whitney test was used for homogeneity evaluations between the COC non-user (control) and COC user groups when entering the study, with a fixed significance level of 5%.</p><p>The percentages of median variation in BMD and BMC were compared between the groups at 12&#x000a0;months after the initial measurements were taken.</p></sec></sec><sec id="Sec4" sec-type="results"><title>Results</title><p>Among the COC users, 35 completed the study and six were excluded because they opted to discontinue COC use. All 26 individuals in the control group completed the study. There were no significant differences between the groups for age, BA, anthropometric variables, and variables obtained by bone densitometry (Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>) at baseline. The mean calcium ingestion was 563.21&#x000a0;mg/day in both groups, which was lower than the value of 1300&#x000a0;mg/day [<xref ref-type="bibr" rid="CR22">22</xref>] recommended in the dietary reference intake (DRI) values. The mean menarche age was similar between the groups and also similar to the mean age of 12.2&#x000a0;years reported for the Brazilian population [<xref ref-type="bibr" rid="CR23">23</xref>]. In the COC group, the median time interval between menarche and starting COC use (gynecological age) was 48&#x000a0;months, and the median serum estradiol level after 6&#x000a0;months of COC use was 10&#x000a0;pg/mL. These values were comparable to those already reported in the literature for this population [<xref ref-type="bibr" rid="CR24">24</xref>].<table-wrap id="Tab1"><label>Table 1</label><caption><p>
<bold>Control and COC user group characteristics at baseline (median, minimum, and maximum values)</bold>
</p></caption><table frame="hsides" rules="groups"><thead><tr valign="top"><th/><th colspan="3">
<bold>Non COC (n&#x02009;=&#x02009;26)</bold>
</th><th colspan="3">
<bold>COC Users (n&#x02009;=&#x02009;35)</bold>
</th><th rowspan="2">
<bold><italic>P</italic></bold>
</th></tr><tr valign="top"><th/><th>
<bold>Median</bold>
</th><th>
<bold>Minimum</bold>
</th><th>
<bold>Maximum</bold>
</th><th>
<bold>Median</bold>
</th><th>
<bold>Minimum</bold>
</th><th>
<bold>Maximum</bold>
</th></tr></thead><tbody><tr valign="top"><td>Age (years)</td><td>15.63</td><td>14.67</td><td>16.08</td><td>15.75</td><td>11.75</td><td>19.50</td><td>
<italic>0.533</italic>
</td></tr><tr valign="top"><td>Bone age (years)</td><td>16.00</td><td>14.00</td><td>18.00</td><td>16.50</td><td>14.00</td><td>18.00</td><td>
<italic>0.604</italic>
</td></tr><tr valign="top"><td>Weight (Kg)</td><td>51.90</td><td>42.60</td><td>64.70</td><td>52.20</td><td>41.00</td><td>73.40</td><td>
<italic>0.839</italic>
</td></tr><tr valign="top"><td>Height (m)</td><td>1.64</td><td>1.51</td><td>1.72</td><td>1.59</td><td>1.49</td><td>1.67</td><td>
<italic>0.101</italic>
</td></tr><tr valign="top"><td>BMI (Kg/m2)</td><td>20.02</td><td>16.69</td><td>24.03</td><td>20.88</td><td>16.63</td><td>27.82</td><td>
<italic>0.233</italic>
</td></tr><tr valign="top"><td>Z-score for BMI</td><td>&#x02212;0.08</td><td>&#x02212;1.40</td><td>0.94</td><td>0.26</td><td>&#x02212;1.93</td><td>1.94</td><td>
<italic>0.255</italic>
</td></tr><tr valign="top"><td>BMI (percentile)</td><td>47.08</td><td>8.07</td><td>82.71</td><td>60.23</td><td>2.66</td><td>97.38</td><td>
<italic>0.279</italic>
</td></tr><tr valign="top"><td>Lumbar BMD (g/cm<sup>2</sup>)</td><td>0.85</td><td>0.76</td><td>1.12</td><td>0.96</td><td>0.77</td><td>1.09</td><td>
<italic>0.228</italic>
</td></tr><tr valign="top"><td>Lumbar BMC (g)</td><td>46.37</td><td>39.90</td><td>76.64</td><td>49.82</td><td>37.70</td><td>64.80</td><td>
<italic>0.330</italic>
</td></tr><tr valign="top"><td>Total body BMD (g/cm<sup>2</sup>)</td><td>1.00</td><td>0.86</td><td>1.18</td><td>1.00</td><td>0.85</td><td>1.13</td><td>
<italic>0.369</italic>
</td></tr><tr valign="top"><td>Total body BMC (g)</td><td>1783.62</td><td>1260.69</td><td>2473.26</td><td>1831.42</td><td>1291.25</td><td>2130.32</td><td>
<italic>0.855</italic>
</td></tr><tr valign="top"><td>Subtotal BMD (g/cm<sup>2</sup>)</td><td>0.88</td><td>0.75</td><td>1.04</td><td>0.87</td><td>0.73</td><td>0.95</td><td>
<italic>0.503</italic>
</td></tr><tr valign="top"><td>Subtotal BMC (g)</td><td>1320.19</td><td>923.07</td><td>1860.11</td><td>1407.01</td><td>945.38</td><td>1609.56</td><td>
<italic>0.903</italic>
</td></tr><tr valign="top"><td>Total body fat (g)</td><td>15075.80</td><td>9539.10</td><td>22160.10</td><td>16111.70</td><td>8504.00</td><td>25681.00</td><td>
<italic>0.976</italic>
</td></tr><tr valign="top"><td>Lean weight (g)</td><td>33051.00</td><td>13852.00</td><td>40656.80</td><td>36735.60</td><td>29604.00</td><td>47615.70</td><td>
<italic>0.016</italic>
</td></tr><tr valign="top"><td>Total body fat (%)</td><td>30.10</td><td>21.10</td><td>37.70</td><td>29.50</td><td>19.60</td><td>38.00</td><td>
<italic>0.637</italic>
</td></tr></tbody></table><table-wrap-foot><p>Mann&#x02013;Whitney test, p&#x02009;&#x0003c;&#x02009;0.05 indicates significant differences.</p></table-wrap-foot></table-wrap></p><p>In the COC group, height did not vary between the measurements taken at baseline and after 12&#x000a0;months. Although the median weight showed a significant increase (p&#x02009;&#x0003c;&#x02009;0.001) in this group, the Z-scores and BMI percentiles did not differ significantly. The weight, height, and BMI percentage values in the control group did not show significant differences between the measurements taken at baseline and after 12&#x000a0;months.</p><p>At the end of the study, the COC users presented with low variations between the initial and final values for lumbar spine BMD and BMC of +2.07% and +1.57%, respectively, while the control group presented with variations of +12.16% (p&#x02009;=&#x02009;0.056) and +16.84% (p&#x02009;=&#x02009;0.014), respectively. The total body BMD and BMC values varied by +0.84% and +1.22% in the COC group, respectively, and were considerably lower than the values of +5.28% and +11.34% in the control group, respectively. The subtotal whole body BMD and BMC values showed a similar variation pattern to the total values. Specifically, the subtotal BMD and BMC values varied by 0.56% and 1.18% in the COC group, and 5.28% and 16.04% in the control group, respectively. Table&#x000a0;<xref rid="Tab2" ref-type="table">2</xref> shows the absolute differences in the variations between the groups, with the lumbar spine BMC (15.27%), subtotal whole body BMC (14.86%), and whole body BMC (10.12%) being the most affected values. Statistical significance (p&#x02009;&#x0003c;&#x02009;0.05) was observed for the variations in BMC between the COC user and non-user groups, but not for the variations in BMD.<table-wrap id="Tab2"><label>Table 2</label><caption><p>
<bold>Comparison of variations in DXA between the control group and COC users at baseline and after 12&#x000a0;months</bold>
</p></caption><table frame="hsides" rules="groups"><thead><tr valign="top"><th rowspan="2">
<bold>Variable</bold>
</th><th colspan="3">
<bold>Non COC</bold>
</th><th colspan="3">
<bold>COC users</bold>
</th><th rowspan="2">
<bold>Difference</bold>
<sup><bold>(1)</bold></sup>
</th><th rowspan="2">
<bold><italic>P</italic></bold>
</th></tr><tr valign="top"><th>
<bold>Initial</bold>
</th><th>
<bold>Final</bold>
</th><th>
<bold>Variation (%)</bold>
</th><th>
<bold>Initial</bold>
</th><th>
<bold>Final</bold>
</th><th>
<bold>Variation (%)</bold>
</th></tr></thead><tbody><tr valign="top"><td>Lumbar BMD (g/cm<sup>2</sup>)</td><td>0.854</td><td>0.958</td><td>12.16</td><td>0.959</td><td>0.949</td><td>2.07</td><td>10.09</td><td>
<italic>0.056</italic>
</td></tr><tr valign="top"><td>Lumbar BMC (g)</td><td>46.37</td><td>53.73</td><td>16.84</td><td>49.82</td><td>49.03</td><td>1.57</td><td>15.27</td><td>
<italic>0.014</italic>
</td></tr><tr valign="top"><td>Subtotal BMD (g/cm<sup>2</sup>)</td><td>0.879</td><td>0.903</td><td>5.28</td><td>0.874</td><td>0.869</td><td>0.56</td><td>4.72</td><td>
<italic>0.149</italic>
</td></tr><tr valign="top"><td>Subtotal BMC (g)</td><td>1320.18</td><td>1538.46</td><td>16.04</td><td>1407.01</td><td>1414.69</td><td>1.18</td><td>14.86</td><td>
<italic>0.033</italic>
</td></tr><tr valign="top"><td>Whole body BMD (g/cm<sup>2</sup>)</td><td>1.003</td><td>1.042</td><td>5.28</td><td>0.995</td><td>0.992</td><td>0.84</td><td>4.44</td><td>
<italic>0.149</italic>
</td></tr><tr valign="top"><td>Whole body BMC (g)</td><td>1783.62</td><td>2006.98</td><td>11.34</td><td>1831.42</td><td>1849.58</td><td>1.22</td><td>10.12</td><td>
<italic>0.031</italic>
</td></tr></tbody></table><table-wrap-foot><p>Variation (in %) at the final moment in relation to the initial moment.</p><p>Absolute difference between variations<sup>(1)</sup>.</p><p>Mann&#x02013;Whitney test; p&#x02009;&#x0003c;&#x02009;0.05 indicates significant differences.</p></table-wrap-foot></table-wrap></p></sec><sec id="Sec5" sec-type="discussion"><title>Discussion</title><p>Adequate bone accretion during adolescence is a potential protective factor against the development of osteopenia and/or osteoporosis later in life. Studies on the impacts of COC use on bone accretion are important to clarify whether adolescents taking COCs are at greater risk of developing osteopenia and/or osteoporosis upon reaching menopause. We took a different approach to those previously found in the literature, as we studied a group of adolescents rather than young adults, and tried to exclude those factors known to interfere with bone mass acquisition, such as tobacco and alcohol use. The use of a standardized COC formulation was adopted to avoid different EE doses or different progestagens.</p><p>After 1&#x000a0;year of taking a low-dose COC (20&#x000a0;&#x003bc;g EE/150&#x000a0;&#x003bc;g desogestrel), the adolescents in the test group presented small variations in BMD and BMC in the lumbar spine region, while those in the control group exhibited higher variations, which translated as the expected bone mass acquisition during this stage of life. The BMC variations between the control and test groups differed significantly (p&#x02009;&#x0003c;&#x02009;0.05), while the BMD variations did not. These results reinforce the negative impact of COCs on bone mass acquisition, because the adolescent COC users clearly exhibited lower bone mass acquisition in the lumbar spine region, subtotal whole body, and whole body when compared with the adolescents in the control group. Even though no significant BMD differences were observed between the groups, the variations in bone mass acquisition between the groups were noteworthy. For example, the control group gained 5.28% in subtotal BMD while the test group gained 0.56%, and the control group gained 5.28% in whole body BMD while the test group gained 0.84%. Such variations are noteworthy, even though we cannot pinpoint the biological mechanisms that might be related to these variations or suggest their true meaning at this point in time. In any case, our findings corroborate the data reported in other studies showing that use of COCs at dosages of &#x02264;30&#x000a0;&#x003bc;g EE can interfere with BMD and BMC values in adolescents, reducing normal bone accretion during this stage of life [<xref ref-type="bibr" rid="CR8">8</xref>,<xref ref-type="bibr" rid="CR16">16</xref>,<xref ref-type="bibr" rid="CR25">25</xref>,<xref ref-type="bibr" rid="CR26">26</xref>].</p><p>Recently, Cibula et al. [<xref ref-type="bibr" rid="CR27">27</xref>] found significantly higher lumbar spine BMD values in COC non-users than in COC users, and higher lumbar BMD in those receiving a higher EE dose, in a study performed on 56 adolescents aged between 15 and 19.5&#x000a0;years. In that study, the authors used a single progestagen associated with different EE doses and observed less bone mass acquisition in the group receiving the lower estrogen dose, suggesting that bone mass accrual depends on estrogen levels. Our findings also revealed changes in bone mass acquisition through analyses of spine BMD and BMC, which were greater in COC non-users than in COC users. These findings can be explained by the fact that trabecular bone, which is considered to be the most important component in vertebra formation and one that has intense remodeling capacity, is more susceptible to interventions than other bones and is also highly affected by estrogen actions [<xref ref-type="bibr" rid="CR26">26</xref>,<xref ref-type="bibr" rid="CR28">28</xref>,<xref ref-type="bibr" rid="CR29">29</xref>].</p><p>The change in physiological estrogen production caused by hypothalamic&#x02013;pituitary&#x02013;gonadal axis blockade, which results from COC use when associated with low EE concentrations, as found in commonly used formulations, seems to play a fundamental role in low bone accretion in adolescents [<xref ref-type="bibr" rid="CR30">30</xref>]. Elevated estrogen levels during adolescence, which occur in girls who develop normally during puberty, seem to be positively related to increased BMD [<xref ref-type="bibr" rid="CR31">31</xref>]. However, during COC use, adolescents presented with estradiol levels that were compatible with the early follicular phase of the menstrual cycle, although the method used here for estradiol measurement was influenced by the levels of interferent content, in this case EE. The adolescents did not reach the elevated levels found in the ovulation phase [<xref ref-type="bibr" rid="CR24">24</xref>,<xref ref-type="bibr" rid="CR32">32</xref>]. The estradiol concentrations seen in COC users in our study seem to confirm this hypothesis. It is known that healthy adolescents at the end of puberty present with mean estradiol levels of 87&#x000a0;pg/mL in the follicular phase, reaching ovulatory values of 150&#x02013;350&#x000a0;pg/mL [<xref ref-type="bibr" rid="CR33">33</xref>]. On the other hand, some authors described that EE exerts a complex inhibitory effect on periosteal apposition, suggesting that this hypothesis is more plausible. Doubts remain and the bone responses are probably the result of multiple factors [<xref ref-type="bibr" rid="CR34">34</xref>,<xref ref-type="bibr" rid="CR35">35</xref>]. A study covering a longer period during adolescence may shed light on the lasting effects of COC use on bone accretion. On the other hand, the use of low EE doses later in life has been reported to promote bone mass acquisition in premenopausal or postmenopausal women [<xref ref-type="bibr" rid="CR36">36</xref>]. Differences in the actions of endogenous and exogenous estrogen have been demonstrated by Coutant et al. [<xref ref-type="bibr" rid="CR37">37</xref>] who followed up adolescents at different stages of puberty in another clinical situation. The authors showed that endogenous gonadal steroid secretion increased growth hormone sensitivity in peripubertal normal short girls, while exogenous oral estrogen administered as 17&#x003b2;-estradiol (2&#x000a0;mg once daily) produced a relative decrease or no change in growth hormone sensitivity. The authors concluded that sex steroid concentrations may have exceeded the physiological ranges for the corresponding age [<xref ref-type="bibr" rid="CR37">37</xref>]. A similar hypothesis can be suggested in our study, as we could not distinguish the action of endogenous estrogen from that of exogenous estrogen. We should also remember that the ER-binding affinity using an identical method for EE relative to E2 was indicated as 1.2:1, respectively, which may result in different responses in target tissues [<xref ref-type="bibr" rid="CR38">38</xref>]. Experimental studies in rats have suggested that bone tissue is less sensitive to estrogen than the uterus and hypothalamic&#x02013;pituitary&#x02013;gonadal axis, indicating that low concentrations of estrogen may block the axis, thereby maintaining uterine trophism, but may not be sufficient to maintain or stimulate adequate bone mass acquisition [<xref ref-type="bibr" rid="CR39">39</xref>].</p><p>The meaning of the effects of the progestagenic component in COCs on bone mass is still poorly understood [<xref ref-type="bibr" rid="CR8">8</xref>,<xref ref-type="bibr" rid="CR30">30</xref>,<xref ref-type="bibr" rid="CR40">40</xref>], owing to difficulties in discriminating between the direct effects of the progestagen on bone, and the effects from alterations in estrogen levels induced by hormonal contraception. Studies have shown that progesterone should act together with estrogen in bone accretion, thereby optimizing the peak bone mass acquisition that occurs in adolescence [<xref ref-type="bibr" rid="CR41">41</xref>]. Therefore, different progestagen components in COCs could hypothetically influence adolescent BMD and BMC values in different ways. Injectable progestagenic contraceptives, such as Depot medroxyprogesterone acetate (DMPA), have a well-documented negative effect on bone mass acquisition [<xref ref-type="bibr" rid="CR40">40</xref>,<xref ref-type="bibr" rid="CR42">42</xref>]. Inhibition of the hypothalamic&#x02013;pituitary&#x02013;gonadal axis has been reported among the mechanisms of action for DMPA, which results in a state of hypogonadism, as well as DMPA binding to glucocorticoid receptors, with a reduction in osteoblast activity [<xref ref-type="bibr" rid="CR43">43</xref>].</p><p>However, when used in association with estrogen supplementation during adolescence, the bone mass reduction is minimized [<xref ref-type="bibr" rid="CR44">44</xref>]. Thus, the low bone acquisition associated with COC use in adolescence seems to be caused by low EE doses [<xref ref-type="bibr" rid="CR45">45</xref>]. However, there is no available evidence in the scientific literature about how progestagens, when present in COC formulations, can affect bone metabolism.</p><p>The effects of DMPA administration on bone mass seem to be reversible because normal BMD is reestablished at 2&#x02013;3 years after its cessation [<xref ref-type="bibr" rid="CR46">46</xref>].</p><p>This study has associated limitations that include the limited period of 1&#x000a0;year of COC use and the lack of BMD evaluation in adolescents with interrupted COC use, which could have indicated whether inappropriate bone mass incorporation associated with COC use can be reverted. Furthermore, we are aware that our results are based on a small number of adolescents using COCs and that they need to be interpreted with caution. Nevertheless, this study permits the inference with some limitations that a reduction in bone accretion occurred during the use of COC in adolescents who had not yet achieved their peak bone mass.</p><p>The clinical relevance of ascertaining low bone accretion in adolescent COC users is still under debate. The risk of fractures in COC users during the second decade of life has not been reported to be higher than that in COC non-users [<xref ref-type="bibr" rid="CR47">47</xref>]. However, there are no current data in the literature showing that the expected maximum bone mass during adolescence can be reverted when the COC is no longer taken, or the outcomes for COC users as they become elderly people. Thus, the future consequences of the low bone mass acquisition in COC users during the critical period of peak bone mass development remain unknown [<xref ref-type="bibr" rid="CR48">48</xref>,<xref ref-type="bibr" rid="CR49">49</xref>].</p></sec><sec id="Sec6" sec-type="conclusion"><title>Conclusions</title><p>Considering the importance of hormonal contraception in adolescents for preventing unplanned pregnancies, new studies are required to establish which estrogenic and progestagenic components, and their ideal doses, would be safe and adequate for appropriate bone mass acquisition in this age group to favor complete development of the bone mineral capital, a protective factor against osteopenia and/or osteoporosis in later life.</p></sec></body><back><fn-group><fn><p><bold>Competing interest</bold></p><p>The authors declare that they have no competing interests.</p></fn><fn><p><bold>Authors&#x02019; contribution</bold></p><p>TPB, TBG, CSK, MRM have equal responsibility in this study. AST: radiologist of the study. HR deCN: statistical consultant. All authors read and approved the final manuscript.</p></fn></fn-group><ack><title>Acknowledgements</title><p>Supported by FAPESP (Funda&#x000e7;&#x000e3;o de Amparo &#x000e0; Pesquisa do Estado de S&#x000e3;o Paulo; Grant 2011/05991-0), Pr&#x000f3; Reitoria de Pesquisa da UNESP, and FUNDUNESP.</p></ack><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Looker</surname><given-names>A</given-names></name><name><surname>Marcus</surname><given-names>R</given-names></name><name><surname>Matkovic</surname><given-names>V</given-names></name><name><surname>Weaver</surname><given-names>C</given-names></name></person-group><article-title>Peak bone mass</article-title><source>Osteoporos Int</source><year>2000</year><volume>11</volume><fpage>985</fpage><lpage>1009</lpage><pub-id pub-id-type="doi">10.1007/s001980070088</pub-id><pub-id pub-id-type="pmid">11256898</pub-id></element-citation></ref><ref id="CR2"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Leonard</surname><given-names>MB</given-names></name><name><surname>Zemel</surname><given-names>BS</given-names></name></person-group><article-title>Current concepts in pediatric bone disease</article-title><source>Pediatr Clin North Am</source><year>2002</year><volume>49</volume><fpage>143</fpage><lpage>73</lpage><pub-id pub-id-type="doi">10.1016/S0031-3955(03)00113-5</pub-id><pub-id pub-id-type="pmid">11826803</pub-id></element-citation></ref><ref id="CR3"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Riggs</surname><given-names>BL</given-names></name><name><surname>Khosla</surname><given-names>S</given-names></name><name><surname>Melton</surname><given-names>LJ</given-names><suffix>3rd</suffix></name></person-group><article-title>Sex steroids and the construction and conservation of the adult skeleton</article-title><source>Endocr Rev</source><year>2002</year><volume>23</volume><fpage>279</fpage><lpage>302</lpage><pub-id pub-id-type="doi">10.1210/edrv.23.3.0465</pub-id><pub-id pub-id-type="pmid">12050121</pub-id></element-citation></ref><ref id="CR4"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rizzoli</surname><given-names>R</given-names></name><name><surname>Bianchi</surname><given-names>ML</given-names></name><name><surname>Garab&#x000e9;dian</surname><given-names>M</given-names></name><name><surname>McKay</surname><given-names>HA</given-names></name><name><surname>Moreno</surname><given-names>LA</given-names></name></person-group><article-title>Maximizing bone mineral mass gain during growth for the prevention of fractures in the adolescents and the elderly</article-title><source>Bone</source><year>2010</year><volume>46</volume><fpage>294</fpage><lpage>305</lpage><pub-id pub-id-type="doi">10.1016/j.bone.2009.10.005</pub-id><pub-id pub-id-type="pmid">19840876</pub-id></element-citation></ref><ref id="CR5"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Saggese</surname><given-names>G</given-names></name><name><surname>Baroncelli</surname><given-names>GI</given-names></name><name><surname>Bertelloni</surname><given-names>S</given-names></name></person-group><article-title>Osteoporosis in children and adolescents: diagnosis, risk factors, and prevention</article-title><source>J Pediatr Endocrinol Metab</source><year>2001</year><volume>14</volume><fpage>833</fpage><lpage>59</lpage><pub-id pub-id-type="doi">10.1515/JPEM.2001.14.7.833</pub-id><pub-id pub-id-type="pmid">11515725</pub-id></element-citation></ref><ref id="CR6"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Duren</surname><given-names>DL</given-names></name><name><surname>Blangero</surname><given-names>J</given-names></name><name><surname>Sherwood</surname><given-names>RJ</given-names></name><name><surname>Seselj</surname><given-names>M</given-names></name><name><surname>Dyer</surname><given-names>T</given-names></name><name><surname>Cole</surname><given-names>SA</given-names></name><etal/></person-group><article-title>Cortical bone health shows significant linkage to chromosomes 2p, 3p, and 17q in 10-year-old children</article-title><source>Bone</source><year>2011</year><volume>49</volume><fpage>1213</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1016/j.bone.2011.08.024</pub-id><pub-id pub-id-type="pmid">21907839</pub-id></element-citation></ref><ref id="CR7"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ma</surname><given-names>NS</given-names></name><name><surname>Gordon</surname><given-names>CM</given-names></name></person-group><article-title>Pediatric osteoporosis: where are we now?</article-title><source>J Pediatr</source><year>2012</year><volume>161</volume><fpage>983</fpage><lpage>90</lpage><pub-id pub-id-type="doi">10.1016/j.jpeds.2012.07.057</pub-id><pub-id pub-id-type="pmid">22974578</pub-id></element-citation></ref><ref id="CR8"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hartard</surname><given-names>M</given-names></name><name><surname>Kleinmond</surname><given-names>C</given-names></name><name><surname>Wiseman</surname><given-names>M</given-names></name><name><surname>Weissenbacher</surname><given-names>ER</given-names></name><name><surname>Felsenberg</surname><given-names>D</given-names></name><name><surname>Erben</surname><given-names>RG</given-names></name></person-group><article-title>Detrimental effect of oral contraceptives on parameters of bone mass and geometry in a cohort of 248 young women</article-title><source>Bone</source><year>2007</year><volume>40</volume><fpage>444</fpage><lpage>50</lpage><pub-id pub-id-type="doi">10.1016/j.bone.2006.08.001</pub-id><pub-id pub-id-type="pmid">16965947</pub-id></element-citation></ref><ref id="CR9"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chow</surname><given-names>J</given-names></name><name><surname>Tobias</surname><given-names>JH</given-names></name><name><surname>Colston</surname><given-names>KW</given-names></name><name><surname>Chambers</surname><given-names>TJ</given-names></name></person-group><article-title>Estrogen maintains trabecular bone volume in rats not only by suppression of bone resorption but also by stimulation of bone formation</article-title><source>J Clin Invest</source><year>1992</year><volume>89</volume><fpage>74</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1172/JCI115588</pub-id><pub-id pub-id-type="pmid">1729283</pub-id></element-citation></ref><ref id="CR10"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hughes</surname><given-names>DE</given-names></name><name><surname>Dai</surname><given-names>A</given-names></name><name><surname>Tiffee</surname><given-names>JC</given-names></name><name><surname>Li</surname><given-names>HH</given-names></name><name><surname>Mundy</surname><given-names>GR</given-names></name><name><surname>Boyce</surname><given-names>BF</given-names></name></person-group><article-title>Estrogen promotes apoptosis of murine osteoclasts mediated by TGF-beta</article-title><source>Nat Med</source><year>1996</year><volume>2</volume><fpage>1132</fpage><lpage>6</lpage><pub-id pub-id-type="doi">10.1038/nm1096-1132</pub-id><pub-id pub-id-type="pmid">8837613</pub-id></element-citation></ref><ref id="CR11"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Manolagas</surname><given-names>SC</given-names></name></person-group><article-title>Birth and death of bone cells: basic regulatory mechanisms and implications for the pathogenesis and treatment of osteoporosis</article-title><source>Endocr Rev</source><year>2000</year><volume>21</volume><fpage>115</fpage><lpage>37</lpage><pub-id pub-id-type="pmid">10782361</pub-id></element-citation></ref><ref id="CR12"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Taranta</surname><given-names>A</given-names></name><name><surname>Brama</surname><given-names>M</given-names></name><name><surname>Teti</surname><given-names>A</given-names></name><name><surname>De Luca</surname><given-names>V</given-names></name><name><surname>Scandurra</surname><given-names>R</given-names></name><name><surname>Spera</surname><given-names>G</given-names></name><etal/></person-group><article-title>The selective estrogen receptor modulator raloxifene regulates osteoclast and osteoblast activity in vitro</article-title><source>Bone</source><year>2002</year><volume>30</volume><fpage>368</fpage><lpage>76</lpage><pub-id pub-id-type="doi">10.1016/S8756-3282(01)00685-8</pub-id><pub-id pub-id-type="pmid">11856644</pub-id></element-citation></ref><ref id="CR13"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Viereck</surname><given-names>V</given-names></name><name><surname>Gr&#x000fc;ndker</surname><given-names>C</given-names></name><name><surname>Blaschke</surname><given-names>S</given-names></name><name><surname>Niederkleine</surname><given-names>B</given-names></name><name><surname>Siggelkow</surname><given-names>H</given-names></name><name><surname>Frosch</surname><given-names>KH</given-names></name><etal/></person-group><article-title>Raloxifene concurrently stimulates osteoprotegerin and inhibits Interleukin-6 production by human trabecular osteoblasts</article-title><source>J Clin Endocrinol Metab</source><year>2003</year><volume>88</volume><fpage>4206</fpage><lpage>13</lpage><pub-id pub-id-type="doi">10.1210/jc.2002-021877</pub-id><pub-id pub-id-type="pmid">12970288</pub-id></element-citation></ref><ref id="CR14"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mosher</surname><given-names>WD</given-names></name><name><surname>Jones</surname><given-names>J</given-names></name></person-group><article-title>Use of contraception in the United States: 1982&#x02013;2008</article-title><source>Vital Health Stat 23</source><year>2010</year><volume>29</volume><fpage>1</fpage><lpage>44</lpage><pub-id pub-id-type="pmid">20939159</pub-id></element-citation></ref><ref id="CR15"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gai</surname><given-names>L</given-names></name><name><surname>Jia</surname><given-names>Y</given-names></name><name><surname>Zhang</surname><given-names>M</given-names></name><name><surname>Gai</surname><given-names>P</given-names></name><name><surname>Wang</surname><given-names>S</given-names></name><name><surname>Shi</surname><given-names>H</given-names></name><etal/></person-group><article-title>Effect of two kinds of different combined oral contraceptives use on bone mineral density in adolescent women</article-title><source>Contraception</source><year>2012</year><volume>86</volume><fpage>332</fpage><lpage>6</lpage><pub-id pub-id-type="doi">10.1016/j.contraception.2012.01.009</pub-id><pub-id pub-id-type="pmid">22364818</pub-id></element-citation></ref><ref id="CR16"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pikkarainen</surname><given-names>E</given-names></name><name><surname>Lehtonen-Veromaa</surname><given-names>M</given-names></name><name><surname>M&#x000f6;tt&#x000f6;nen</surname><given-names>T</given-names></name><name><surname>Kautiainen</surname><given-names>H</given-names></name><name><surname>Viikari</surname><given-names>J</given-names></name></person-group><article-title>Estrogen-progestin contraceptive use during adolescence prevents bone mass acquisition: a 4-year follow-up study</article-title><source>Contraception</source><year>2008</year><volume>78</volume><fpage>226</fpage><lpage>31</lpage><pub-id pub-id-type="doi">10.1016/j.contraception.2008.05.002</pub-id><pub-id pub-id-type="pmid">18692613</pub-id></element-citation></ref><ref id="CR17"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hartman</surname><given-names>LB</given-names></name><name><surname>Monasterio</surname><given-names>E</given-names></name><name><surname>Hwang</surname><given-names>LY</given-names></name></person-group><article-title>Adolescent contraception: review and guidance for pediatric clinicians</article-title><source>Curr Probl Pediatr Adolesc Health Care</source><year>2012</year><volume>42</volume><fpage>221</fpage><lpage>63</lpage><pub-id pub-id-type="doi">10.1016/j.cppeds.2012.05.001</pub-id><pub-id pub-id-type="pmid">22959636</pub-id></element-citation></ref><ref id="CR18"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kuczmarski</surname><given-names>RJ</given-names></name><name><surname>Ogden</surname><given-names>CL</given-names></name><name><surname>Guo</surname><given-names>SS</given-names></name><name><surname>Grummer-Strawn</surname><given-names>LM</given-names></name><name><surname>Flegal</surname><given-names>KM</given-names></name><name><surname>Mei</surname><given-names>Z</given-names></name><etal/></person-group><article-title>2000 CDC growth charts for the United States: methods and development</article-title><source>Vital Health Stat 11</source><year>2002</year><volume>246</volume><fpage>1</fpage><lpage>190</lpage><pub-id pub-id-type="pmid">12043359</pub-id></element-citation></ref><ref id="CR19"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Marshall</surname><given-names>WA</given-names></name><name><surname>Tanner</surname><given-names>JM</given-names></name></person-group><article-title>Variations in pattern of pubertal changes in girls</article-title><source>Arch Dis Child</source><year>1969</year><volume>44</volume><fpage>291</fpage><lpage>303</lpage><pub-id pub-id-type="doi">10.1136/adc.44.235.291</pub-id><pub-id pub-id-type="pmid">5785179</pub-id></element-citation></ref><ref id="CR20"><label>20.</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Greulich</surname><given-names>WW</given-names></name><name><surname>Pyle</surname><given-names>SI</given-names></name></person-group><source>Radiographic atlas of skeletal development of the hand and wrist</source><year>1959</year><edition>2</edition><publisher-loc>Palo Alto, CA</publisher-loc><publisher-name>Stanford University Press</publisher-name></element-citation></ref><ref id="CR21"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bianchi</surname><given-names>ML</given-names></name><name><surname>Baim</surname><given-names>S</given-names></name><name><surname>Bishop</surname><given-names>NJ</given-names></name><name><surname>Gordon</surname><given-names>CM</given-names></name><name><surname>Hans</surname><given-names>DB</given-names></name><name><surname>Langman</surname><given-names>CB</given-names></name><etal/></person-group><article-title>Official positions of the international society for clinical densitometry (ISCD) on DXA evaluation in children and adolescents</article-title><source>Pediatr Nephrol</source><year>2010</year><volume>25</volume><fpage>37</fpage><lpage>47</lpage><pub-id pub-id-type="doi">10.1007/s00467-009-1249-z</pub-id><pub-id pub-id-type="pmid">19603190</pub-id></element-citation></ref><ref id="CR22"><label>22.</label><mixed-citation publication-type="other">Institute of Medicine (US) Committee to Review Dietary Reference Intakes for Vitamin D and Calcium; Ross AC, Taylor CL, Yaktine AL, Del Valle HB, editors. Dietary Reference Intakes for Calcium and Vitamin D. Washington (DC): National Academies Press (US); 2011. [<ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/books/NBK56070/">http://www.ncbi.nlm.nih.gov/books/NBK56070/</ext-link>]</mixed-citation></ref><ref id="CR23"><label>23.</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Colli</surname><given-names>AS</given-names></name></person-group><article-title>Crescimento e desenvolvimento f&#x000ed;sico</article-title><source>Comiss&#x000e3;o de Sa&#x000fa;de do Adolescente da Secretaria de Estado da Sa&#x000fa;de de S&#x000e3;o Paulo</source><year>1988</year><publisher-loc>S&#x000e3;o Paulo</publisher-loc><publisher-name>Paris Editorial</publisher-name><fpage>43</fpage><lpage>57</lpage></element-citation></ref><ref id="CR24"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gaspard</surname><given-names>UJ</given-names></name><name><surname>Romus</surname><given-names>MA</given-names></name><name><surname>Gillain</surname><given-names>D</given-names></name><name><surname>Duvivier</surname><given-names>J</given-names></name><name><surname>Demey-Ponsart</surname><given-names>E</given-names></name><name><surname>Franchimont</surname><given-names>P</given-names></name></person-group><article-title>Plasma hormone levels in women receiving new oral contraceptives containing ethinyl estradiol plus levonorgestrel or desogestrel</article-title><source>Contraception</source><year>1983</year><volume>27</volume><fpage>577</fpage><lpage>90</lpage><pub-id pub-id-type="doi">10.1016/0010-7824(83)90023-9</pub-id><pub-id pub-id-type="pmid">6225622</pub-id></element-citation></ref><ref id="CR25"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Polatti</surname><given-names>F</given-names></name><name><surname>Perotti</surname><given-names>F</given-names></name><name><surname>Filippa</surname><given-names>N</given-names></name><name><surname>Gallina</surname><given-names>D</given-names></name><name><surname>Nappi</surname><given-names>RE</given-names></name></person-group><article-title>Bone mass and long-term monophasic oral contraceptive treatment in young women</article-title><source>Contraception</source><year>1995</year><volume>51</volume><fpage>221</fpage><lpage>4</lpage><pub-id pub-id-type="doi">10.1016/0010-7824(95)00036-A</pub-id><pub-id pub-id-type="pmid">7796586</pub-id></element-citation></ref><ref id="CR26"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Almstedt Shoepe</surname><given-names>H</given-names></name><name><surname>Snow</surname><given-names>CM</given-names></name></person-group><article-title>Oral contraceptive use in young women is associated with lower bone mineral density than that of controls</article-title><source>Osteoporos Int</source><year>2005</year><volume>16</volume><fpage>1538</fpage><lpage>44</lpage><pub-id pub-id-type="doi">10.1007/s00198-005-1868-6</pub-id><pub-id pub-id-type="pmid">15902418</pub-id></element-citation></ref><ref id="CR27"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cibula</surname><given-names>D</given-names></name><name><surname>Skrenkova</surname><given-names>J</given-names></name><name><surname>Hill</surname><given-names>M</given-names></name><name><surname>Stepan</surname><given-names>JJ</given-names></name></person-group><article-title>Low-dose estrogen combined oral contraceptives may negatively influence physiological bone mineral density acquisition during adolescence</article-title><source>Eur J Endocrinol</source><year>2012</year><volume>166</volume><fpage>1003</fpage><lpage>11</lpage><pub-id pub-id-type="doi">10.1530/EJE-11-1047</pub-id><pub-id pub-id-type="pmid">22436400</pub-id></element-citation></ref><ref id="CR28"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>van der Sluis</surname><given-names>IM</given-names></name><name><surname>de Muinck Keizer-Schrama</surname><given-names>SM</given-names></name></person-group><article-title>Osteoporosis in childhood: bone density of children in health and disease</article-title><source>J Pediatr Endocrinol Metab</source><year>2001</year><volume>14</volume><fpage>817</fpage><lpage>32</lpage><pub-id pub-id-type="pmid">11515724</pub-id></element-citation></ref><ref id="CR29"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lash</surname><given-names>RW</given-names></name><name><surname>Nicholson</surname><given-names>JM</given-names></name><name><surname>Velez</surname><given-names>L</given-names></name><name><surname>Van Harrison</surname><given-names>R</given-names></name><name><surname>McCort</surname><given-names>J</given-names></name></person-group><article-title>Diagnosis and management of osteoporosis</article-title><source>Prim Care</source><year>2009</year><volume>36</volume><fpage>181</fpage><lpage>98</lpage><pub-id pub-id-type="doi">10.1016/j.pop.2008.10.009</pub-id><pub-id pub-id-type="pmid">19231609</pub-id></element-citation></ref><ref id="CR30"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Agostinho</surname><given-names>K</given-names></name><name><surname>Di Meglio</surname><given-names>G</given-names></name></person-group><article-title>Low-dose oral contraceptives in adolescents: how low can you go?</article-title><source>J Pediatr Adolesc Gynecol</source><year>2010</year><volume>23</volume><fpage>195</fpage><lpage>201</lpage><pub-id pub-id-type="doi">10.1016/j.jpag.2009.11.001</pub-id><pub-id pub-id-type="pmid">20227307</pub-id></element-citation></ref><ref id="CR31"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>Q</given-names></name><name><surname>Nicholson</surname><given-names>PH</given-names></name><name><surname>Suuriniemi</surname><given-names>M</given-names></name><name><surname>Lyytik&#x000e4;inen</surname><given-names>A</given-names></name><name><surname>Helkala</surname><given-names>E</given-names></name><name><surname>Alen</surname><given-names>M</given-names></name><etal/></person-group><article-title>Relationship of sex hormones to bone geometric properties and mineral density in early pubertal girls</article-title><source>J Clin Endocrinol Metab</source><year>2004</year><volume>89</volume><fpage>1698</fpage><lpage>703</lpage><pub-id pub-id-type="doi">10.1210/jc.2003-031113</pub-id><pub-id pub-id-type="pmid">15070933</pub-id></element-citation></ref><ref id="CR32"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lattakova</surname><given-names>M</given-names></name><name><surname>Borovsky</surname><given-names>M</given-names></name><name><surname>Payer</surname><given-names>J</given-names></name><name><surname>Killinger</surname><given-names>Z</given-names></name></person-group><article-title>Oral contraception usage in relation to bone mineral density and bone turnover in adolescent girls</article-title><source>Eur J Contracept Reprod Health Care</source><year>2009</year><volume>14</volume><fpage>207</fpage><lpage>14</lpage><pub-id pub-id-type="doi">10.1080/13625180902838828</pub-id><pub-id pub-id-type="pmid">19565418</pub-id></element-citation></ref><ref id="CR33"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Finkelstein</surname><given-names>JW</given-names></name></person-group><article-title>The endocrinology of adolescence</article-title><source>Pediatr Clin North Am</source><year>1980</year><volume>27</volume><fpage>53</fpage><lpage>69</lpage><pub-id pub-id-type="pmid">6769088</pub-id></element-citation></ref><ref id="CR34"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Scholes</surname><given-names>D</given-names></name><name><surname>Ichikawa</surname><given-names>L</given-names></name><name><surname>LaCroix</surname><given-names>AZ</given-names></name><name><surname>Spangler</surname><given-names>L</given-names></name><name><surname>Beasley</surname><given-names>JM</given-names></name><name><surname>Reed</surname><given-names>S</given-names></name><etal/></person-group><article-title>Oral contraceptive use and bone density in adolescent and young adult women</article-title><source>Contraception</source><year>2010</year><volume>1</volume><fpage>35</fpage><lpage>40</lpage><pub-id pub-id-type="doi">10.1016/j.contraception.2009.07.001</pub-id><pub-id pub-id-type="pmid">20004271</pub-id></element-citation></ref><ref id="CR35"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tr&#x000e9;mollieres</surname><given-names>F</given-names></name></person-group><article-title>Impact of oral contraceptive on bone metabolism</article-title><source>Best Pract Res Clin Endocrinol Metab</source><year>2013</year><volume>27</volume><fpage>47</fpage><lpage>53</lpage><pub-id pub-id-type="doi">10.1016/j.beem.2012.09.002</pub-id><pub-id pub-id-type="pmid">23384745</pub-id></element-citation></ref><ref id="CR36"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Martins</surname><given-names>SL</given-names></name><name><surname>Curtis</surname><given-names>KM</given-names></name><name><surname>Glasier</surname><given-names>AF</given-names></name></person-group><article-title>Combined hormonal contraception and bone health: a systematic review</article-title><source>Contraception</source><year>2006</year><volume>73</volume><fpage>445</fpage><lpage>69</lpage><pub-id pub-id-type="doi">10.1016/j.contraception.2006.01.003</pub-id><pub-id pub-id-type="pmid">16627030</pub-id></element-citation></ref><ref id="CR37"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Coutant</surname><given-names>R</given-names></name><name><surname>de Casson</surname><given-names>FB</given-names></name><name><surname>Rouleau</surname><given-names>S</given-names></name><name><surname>Douay</surname><given-names>O</given-names></name><name><surname>Mathieu</surname><given-names>E</given-names></name><name><surname>Gatelais</surname><given-names>F</given-names></name><etal/></person-group><article-title>Divergent effect of endogenous and exogenous Sex steroids on the insulin-like growth factor I response to growth hormone in short normal adolescents</article-title><source>J Clin Endocrinol Metab</source><year>2004</year><volume>89</volume><fpage>6185</fpage><lpage>92</lpage><pub-id pub-id-type="doi">10.1210/jc.2004-0814</pub-id><pub-id pub-id-type="pmid">15579776</pub-id></element-citation></ref><ref id="CR38"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Churchwell</surname><given-names>MI</given-names></name><name><surname>Camacho</surname><given-names>L</given-names></name><name><surname>Vanlandingham</surname><given-names>MM</given-names></name><name><surname>Twaddle</surname><given-names>NC</given-names></name><name><surname>Sepehr</surname><given-names>E</given-names></name><name><surname>Delclos</surname><given-names>KB</given-names></name><etal/></person-group><article-title>Comparison of life-stage-dependent internal dosimetry for bisphenol A, ethinyl estradiol, a reference estrogen, and endogenous estradiol to test an estrogenic mode of action in Sprague Dawley rats</article-title><source>Toxicol Sci</source><year>2014</year><volume>139</volume><fpage>4</fpage><lpage>20</lpage><pub-id pub-id-type="doi">10.1093/toxsci/kfu021</pub-id><pub-id pub-id-type="pmid">24496641</pub-id></element-citation></ref><ref id="CR39"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Erben</surname><given-names>RG</given-names></name><name><surname>Brunner</surname><given-names>KS</given-names></name><name><surname>Breig</surname><given-names>B</given-names></name></person-group><article-title>Long-term sensitivity of uterus and hypothalamus/pituitary axis to 17beta-estradiol is higher than that of bone in rats</article-title><source>J Bone Miner Res</source><year>2004</year><volume>19</volume><fpage>1827</fpage><lpage>32</lpage><pub-id pub-id-type="doi">10.1359/JBMR.040815</pub-id><pub-id pub-id-type="pmid">15476583</pub-id></element-citation></ref><ref id="CR40"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Walsh</surname><given-names>JS</given-names></name><name><surname>Eastell</surname><given-names>R</given-names></name><name><surname>Peel</surname><given-names>NF</given-names></name></person-group><article-title>Effects of Depot medroxyprogesterone acetate on bone density and bone metabolism before and after peak bone mass: a case&#x02013;control study</article-title><source>J Clin Endocrinol Metab</source><year>2008</year><volume>93</volume><fpage>1317</fpage><lpage>23</lpage><pub-id pub-id-type="doi">10.1210/jc.2007-2201</pub-id><pub-id pub-id-type="pmid">18230659</pub-id></element-citation></ref><ref id="CR41"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Seifert-Klauss</surname><given-names>V</given-names></name><name><surname>Prior</surname><given-names>JC</given-names></name></person-group><article-title>Progesterone and bone: actions promoting bone health in women</article-title><source>J Osteoporos</source><year>2010</year><volume>2010</volume><fpage>845180</fpage><pub-id pub-id-type="doi">10.4061/2010/845180</pub-id><pub-id pub-id-type="pmid">21052538</pub-id></element-citation></ref><ref id="CR42"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cromer</surname><given-names>BA</given-names></name><name><surname>Stager</surname><given-names>M</given-names></name><name><surname>Bonny</surname><given-names>A</given-names></name><name><surname>Lazebnik</surname><given-names>R</given-names></name><name><surname>Rome</surname><given-names>E</given-names></name><name><surname>Ziegler</surname><given-names>J</given-names></name><etal/></person-group><article-title>Depot medroxyprogesterone acetate, oral contraceptives and bone mineral density in a cohort of adolescent girls</article-title><source>J Adolesc Health</source><year>2004</year><volume>35</volume><fpage>434</fpage><lpage>41</lpage><pub-id pub-id-type="doi">10.1016/j.jadohealth.2004.07.005</pub-id><pub-id pub-id-type="pmid">15581522</pub-id></element-citation></ref><ref id="CR43"><label>43.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ishida</surname><given-names>Y</given-names></name><name><surname>Ishida</surname><given-names>Y</given-names></name><name><surname>Heersche</surname><given-names>JN</given-names></name></person-group><article-title>Pharmacologic doses of medroxyprogesterone may cause bone loss through glucocorticoid activity: an hypothesis</article-title><source>Osteoporos Int</source><year>2002</year><volume>13</volume><fpage>601</fpage><lpage>5</lpage><pub-id pub-id-type="doi">10.1007/s001980200080</pub-id><pub-id pub-id-type="pmid">12181616</pub-id></element-citation></ref><ref id="CR44"><label>44.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cromer</surname><given-names>BA</given-names></name><name><surname>Lazebnik</surname><given-names>R</given-names></name><name><surname>Rome</surname><given-names>E</given-names></name><name><surname>Stager</surname><given-names>M</given-names></name><name><surname>Bonny</surname><given-names>A</given-names></name><name><surname>Ziegler</surname><given-names>J</given-names></name><etal/></person-group><article-title>Double-blinded randomized controlled trial of estrogen supplementation in adolescent girls who receive depot medroxyprogesterone acetate for contraception</article-title><source>Am J Obstet Gynecol</source><year>2005</year><volume>192</volume><fpage>42</fpage><lpage>7</lpage><pub-id pub-id-type="doi">10.1016/j.ajog.2004.07.041</pub-id><pub-id pub-id-type="pmid">15672001</pub-id></element-citation></ref><ref id="CR45"><label>45.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nappi</surname><given-names>C</given-names></name><name><surname>Bifulco</surname><given-names>G</given-names></name><name><surname>Tommaselli</surname><given-names>GA</given-names></name><name><surname>Gargano</surname><given-names>V</given-names></name><name><surname>Di Carlo</surname><given-names>C</given-names></name></person-group><article-title>Hormonal contraception and bone metabolism: a systematic review</article-title><source>Contraception</source><year>2012</year><volume>86</volume><fpage>606</fpage><lpage>21</lpage><pub-id pub-id-type="doi">10.1016/j.contraception.2012.04.009</pub-id><pub-id pub-id-type="pmid">22717184</pub-id></element-citation></ref><ref id="CR46"><label>46.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guilbert</surname><given-names>ER</given-names></name><name><surname>Brown</surname><given-names>JP</given-names></name><name><surname>Kaunitz</surname><given-names>AM</given-names></name><name><surname>Wagner</surname><given-names>MS</given-names></name><name><surname>B&#x000e9;rub&#x000e9;</surname><given-names>J</given-names></name><name><surname>Charbonneau</surname><given-names>L</given-names></name><etal/></person-group><article-title>The use of depot-medroxyprogesterone acetate in contraception and its potential impact on skeletal health</article-title><source>Contraception</source><year>2009</year><volume>79</volume><fpage>167</fpage><lpage>77</lpage><pub-id pub-id-type="doi">10.1016/j.contraception.2008.10.016</pub-id><pub-id pub-id-type="pmid">19185668</pub-id></element-citation></ref><ref id="CR47"><label>47.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vestergaard</surname><given-names>P</given-names></name><name><surname>Rejnmark</surname><given-names>L</given-names></name><name><surname>Mosekilde</surname><given-names>L</given-names></name></person-group><article-title>Fracture risk in very young women using combined oral contraceptives</article-title><source>Contraception</source><year>2008</year><volume>78</volume><fpage>358</fpage><lpage>64</lpage><pub-id pub-id-type="doi">10.1016/j.contraception.2008.06.010</pub-id><pub-id pub-id-type="pmid">18929731</pub-id></element-citation></ref><ref id="CR48"><label>48.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moretto de Oliveria</surname><given-names>MR</given-names></name><name><surname>Cristiane da Silva</surname><given-names>C</given-names></name><name><surname>Kurokawa</surname><given-names>CS</given-names></name><name><surname>Teixeira Fortes</surname><given-names>CM</given-names></name><name><surname>Campos Capela</surname><given-names>R</given-names></name><name><surname>Santos Teixeira</surname><given-names>A</given-names></name><etal/></person-group><article-title>Bone mineral density in healthy female adolescents according to age, bone age and pubertal breast stage</article-title><source>Open Orthop J</source><year>2011</year><volume>5</volume><fpage>324</fpage><lpage>30</lpage><pub-id pub-id-type="doi">10.2174/1874325001105010324</pub-id><pub-id pub-id-type="pmid">21966336</pub-id></element-citation></ref><ref id="CR49"><label>49.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fortes</surname><given-names>CM</given-names></name><name><surname>Goldberg</surname><given-names>TB</given-names></name><name><surname>Kurokawa</surname><given-names>CS</given-names></name><name><surname>Silva</surname><given-names>CC</given-names></name><name><surname>Moretto</surname><given-names>MR</given-names></name><name><surname>Biason</surname><given-names>TP</given-names></name><etal/></person-group><article-title>Relationship between chronological and bone ages and pubertal stage of breasts with bone biomarkers and bone mineral density in adolescents</article-title><source>J Pediatr (Rio J)</source><year>2014</year><volume>90</volume><fpage>624</fpage><lpage>31</lpage><pub-id pub-id-type="doi">10.1016/j.jped.2014.04.008</pub-id><pub-id pub-id-type="pmid">25035136</pub-id></element-citation></ref></ref-list></back></article>